Baseline tumour vessel perfusion as a non-invasive predictive biomarker for immune checkpoint therapy in non-small-cell lung cancer
10.1136/bmjonc-2024-000473. 2024;3:e000473 - DOI: 10.1136/bmjonc-2024-000473
Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer.
Leveraging insights from cancer to improve tuberculosis therapy.
Trends Mol Med. 2024;:ePub - PMID: 39142973 - DOI: 10.1016/j.molmed.2024.07.011
Cancer tissue of origin constrains the growth and metabolism of metastases.
Nat Metab. 2024;6(9):1668-1681 - PMID: 39160333 - PMCID: PMC11450831 - DOI: 10.1038/s42255-024-01105-9
Lymphatic system regulation of anti-cancer immunity and metastasis.
Front Immunol. 2024;15:1449291 - PMID: 39211044 - PMCID: PMC11357954 - DOI: 10.3389/fimmu.2024.1449291
Mutant p53 Exploits Enhancers to Elevate Immunosuppressive Chemokine Expression and Impair Immune Checkpoint Inhibitors in Pancreatic Cancer.
Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab.
PEARL: A Phase Ib/II Biomarker Study of Adding Radiation Therapy to Pembrolizumab Before Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
J Clin Oncol. 2024;:JCO2400003 - PMID: 39298718 - DOI: 10.1200/JCO.24.00003
Two decades of advances in clinical oncology - lessons learned and future directions.
Nat Rev Clin Oncol. 2024;21(11):771-780 - PMID: 39354161 - DOI: 10.1038/s41571-024-00945-4
Impact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer.
Clin Genitourin Cancer. 2024;22(5):102143 - PMID: 39032202 - DOI: 10.1016/j.clgc.2024.102143
Losartan rewires the tumor-immune microenvironment and suppresses IGF-1 to overcome resistance to chemo-immunotherapy in ovarian cancer.
Br J Cancer. 2024;:ePub - PMID: 39369055 - DOI: 10.1038/s41416-024-02863-9
Compressive stresses in cancer: characterization and implications for tumour progression and treatment.
Nat Rev Cancer. 2024;24(11):768-791 - PMID: 39390249 - DOI: 10.1038/s41568-024-00745-z
Characterization of cell states in biliary tract cancers identifies mechanisms of therapeutic resistance in a phase II trial of DKN-01/nivolumab.
A Novel Liver Cancer-Selective Histone Deacetylase Inhibitor Is Effective against Hepatocellular Carcinoma and Induces Durable Responses with Immunotherapy.
ACS Pharmacol Transl Sci. 2024;7(10):3155-3169 - PMID: 39416967 - PMCID: PMC11475281 - DOI: 10.1021/acsptsci.4c00358
Tissue and imaging biomarkers of response to neoadjuvant nivolumab or nivolumab plus ipilimumab in patients with resectable hepatocellular carcinoma.
Oncology. 2024;:1-20 - PMID: 39427654 - DOI: 10.1159/000541250
AMBER: A Modular Model for Tumor Growth, Vasculature and Radiation Response.
Bull Math Biol. 2024;86(12):139 - PMID: 39460828 - DOI: 10.1007/s11538-024-01371-4
Site of breast cancer metastasis is independent of single nutrient levels.
A Novel Liver Cancer-Selective Histone Deacetylase Inhibitor Is Effective Against Hepatocellular Carcinoma and Induces Durable Responses with Immunotherapy.
Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy.
Cancer Immunol Res. 2024;12(4):400-412 - PMID: 38260999 - PMCID: PMC10985468 - DOI: 10.1158/2326-6066.CIR-23-0486
Mathematical model of oxygen, nutrient, and drug transport in Tuberculosis Granulomas.
PLoS Comput Biol. 2024;20(2):e1011847 - PMID: 38335224 - PMCID: PMC10883541 - DOI: 10.1371/journal.pcbi.1011847
Unraveling a hidden player in lymphovascular invasion in bladder cancer.
Cancer Cell. 2024;42(4):509-512 - PMID: 38458186 - DOI: 10.1016/j.ccell.2024.02.007
Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma.
J Hepatocell Carcinoma. 2024;11:455-461 - PMID: 38463542 - PMCID: PMC10921889 - DOI: 10.2147/JHC.S452564
Exercise intensity governs tumor control in mice with breast cancer.
Front Immunol. 2024;15:1339232 - PMID: 38495879 - PMCID: PMC10940460 - DOI: 10.3389/fimmu.2024.1339232
In silico clinical studies for optimal COVID-19 vaccination schedules in patients with cancer.
Cell Rep Med. 2024;5(3):101436 - PMID: 38508146 - PMCID: PMC10982978 - DOI: 10.1016/j.xcrm.2024.101436
Normalizing granuloma vasculature and matrix improves drug delivery and reduces bacterial burden in tuberculosis-infected rabbits.
Proc Natl Acad Sci U S A. 2024;121(14):e2321336121 - PMID: 38530888 - PMCID: PMC10998582 - DOI: 10.1073/pnas.2321336121
Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer.
The radiopharmaceutical radium-223 has immunomodulatory effects in patients and facilitates anti-programmed death receptor-1 therapy in murine models of bone metastatic prostate cancer.
Radiother Oncol. 2024;192:110091 - PMID: 38224917 - PMCID: PMC10905770 - DOI: 10.1016/j.radonc.2024.110091
Experimental and theoretical model of microvascular network remodeling and blood flow redistribution following minimally invasive microvessel laser ablation.
Mechanics of Lymphatic Pumping and Lymphatic Function.
Cold Spring Harb Perspect Med. 2024;:ePub - PMID: 38692743 - DOI: 10.1101/cshperspect.a041171
A Multiresolution Approach with Method-Informed Statistical Analysis for Quantifying Lymphatic Pumping Dynamics.
Metabolite profiling of human renal cell carcinoma reveals tissue-origin dominance in nutrient availability.
Dynamic heterogeneity in COVID-19: Insights from a mathematical model.
PLoS One. 2024;19(5):e0301780 - PMID: 38820409 - PMCID: PMC11142552 - DOI: 10.1371/journal.pone.0301780
Fluid dynamics and leukocyte transit in the lymphatic system.
PNAS Nexus. 2024;3(6):pgae195 - PMID: 38827815 - PMCID: PMC11141778 - DOI: 10.1093/pnasnexus/pgae195
Integrating Ataxia Evaluation into Tumor-Induced Hearing Loss Model to Comprehensively Study NF2-Related Schwannomatosis.
Cancers (Basel). 2024;16(11):ePub - PMID: 38893082 - PMCID: PMC11171041 - DOI: 10.3390/cancers16111961
34